Vetter wins the AbbVie TRIUMPH AWARD
Leading CDMO claims prestigious customer award from one of the top-20 biopharmaceutical companies.
AbbVie has awarded Vetter, a leading contract manufacturing and development organization (CDMO), the TRIUMPH AWARD for 2015. The award was granted for meeting AbbVie’s ‘predetermined high-level demands of service’. Vetter received this prestigious award as a contract manufacturer in the category Third-Party Manufacturers - Supplier of the Year. Recently, Vetter announced that the company won two other coveted awards, the WorldStar Award 2016 for its syringe closure system Vetter-Ject, and the 2016 CMO Leadership Award in four categories including, quality, capabilities, expertise, and compatibility.
The AbbVie TRIUMPH AWARD was created to acknowledge contract service companies whose efforts are ‘well-aligned with the company’s business strategy, and make an important contribution to AbbVie’s strategic vision on a long-term basis’. With this award, granted within a field of more than one thousand contractors, the company recognizes its top performing contract suppliers for efforts that consistently add measureable value, and regularly exceed best-in-class performance on behalf of AbbVie and patients who come to rely on their products. Vetter received this prestigious award as a contract manufacturer for 2015 in the category Third-Party Manufacturers — Supplier of the Year. This recognition was achieved by meeting the predetermined high-level demands of service AbbVie has come to expect that is ‘consistently above-average’.
“The winning of this award is especially significant for Vetter as it recognizes our continuing efforts to provide our customers a high-level of service, and it is particularly gratifying since it is from one of the world’s leading biopharmaceutical companies,” said Vetter Managing Director Peter Soelkner. “This award is a reflection of the value that Vetter brings to the biopharmaceutical industry, and consequently to patients worldwide, and is yet another affirmation that Vetter continues to exceed the expectations of our peers in areas of critical importance to their business.” In a speech honoring Vetter for the award, AbbVie highlighted the importance of the good partnership it has forged with Vetter, specifically noting the achievement of a high number of commercial batches, as well as the many project activities performed on the company’s behalf.
Related News
-
News US BIOSECURE Act passed by US House of Representatives
The controversial act, which has already impacted several foreign companies operating in the US, was passed by the House of Representatives on September 9, 2024. It is now headed for the US Senate before it can be signed into law by President Joe Biden... -
News Pharma Supply Chain People Moves
The latest appointments, promotions, and structural changes across the pharmaceutical supply chain. -
News Drug prices agreed upon as part of the US Inflation Reduction Act
The Inflation Reduction Act brought into constitution by the Biden administation in 2022, which proposed a drug price negotiation between the government and pharmaceutical companies, has reached it's first agreement. -
News BIOSECURE Act continues to loom over Chinese pharma manufacturers
With the US BIOSECURE Act on its way to passing into legislation, Chinese companies are facing declining revenues within the first half of 2024 as US pharmaceutical and healthcare companies pull their businesses from the country. -
News Ophthalmologic drug product Eylea faces biosimilar threats after FDA approvals
Regeneron Pharmaceutical’s blockbuster ophthalmology drug Eylea is facing biosimilar competition as the US FDA approves Biocon’s Yesafili and Samsung Bioepis/Biogen’s Opuviz. -
News ONO Pharmaceutical expands oncology portfolio with acquisition of Deciphera
ONO Pharmaceutical, out of Japan, is in the process of acquiring cancer-therapy maker Deciphera Pharmaceuticals for US$2.4 billion. -
News First offers for pharma from Medicare drug price negotiations
Ten high-cost drugs from various pharma manufacturers are in pricing negotiations in a first-ever for the US Medicare program. President Biden’s administration stated they have responded to the first round of offers. -
News Eli Lilly’s Zepbound makes leaps and bounds in weight-loss drug market
In the last week, Eli Lilly has announced their partnership with Amazon.com’s pharmacy unit to deliver prescriptions of Zepbound. Zepbound has also surpassed Novo Nordisk’s Wegovy for the number of prescriptions for the week of March 8.&nbs...
Position your company at the heart of the global Pharma industry with a CPHI Online membership
-
Your products and solutions visible to thousands of visitors within the largest Pharma marketplace
-
Generate high-quality, engaged leads for your business, all year round
-
Promote your business as the industry’s thought-leader by hosting your reports, brochures and videos within your profile
-
Your company’s profile boosted at all participating CPHI events
-
An easy-to-use platform with a detailed dashboard showing your leads and performance